SE9704544D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9704544D0
SE9704544D0 SE9704544A SE9704544A SE9704544D0 SE 9704544 D0 SE9704544 D0 SE 9704544D0 SE 9704544 A SE9704544 A SE 9704544A SE 9704544 A SE9704544 A SE 9704544A SE 9704544 D0 SE9704544 D0 SE 9704544D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pharmaceutical compositions
therapy
preparing
preparation
Prior art date
Application number
SE9704544A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Baxter
Thomas Mcinally
Michael Mortimore
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9704544A priority Critical patent/SE9704544D0/xx
Publication of SE9704544D0 publication Critical patent/SE9704544D0/xx
Priority to KR1020007006132A priority patent/KR20010032814A/ko
Priority to AT98962751T priority patent/ATE224360T1/de
Priority to CN98813491A priority patent/CN1284057A/zh
Priority to SK843-2000A priority patent/SK8432000A3/sk
Priority to AU17913/99A priority patent/AU744280B2/en
Priority to HU0004434A priority patent/HUP0004434A3/hu
Priority to TR2000/01605T priority patent/TR200001605T2/xx
Priority to SI9830276T priority patent/SI1036059T1/xx
Priority to PCT/SE1998/002188 priority patent/WO1999029661A1/en
Priority to EEP200000378A priority patent/EE200000378A/xx
Priority to PT98962751T priority patent/PT1036059E/pt
Priority to DE69808130T priority patent/DE69808130T2/de
Priority to ES98962751T priority patent/ES2184352T3/es
Priority to CA002312420A priority patent/CA2312420A1/en
Priority to JP2000524258A priority patent/JP2001525392A/ja
Priority to IDW20001019A priority patent/ID28003A/id
Priority to IL13636998A priority patent/IL136369A0/xx
Priority to US09/230,478 priority patent/US6201024B1/en
Priority to EP98962751A priority patent/EP1036059B1/en
Priority to RU2000117574/04A priority patent/RU2214997C2/ru
Priority to PL98340906A priority patent/PL340906A1/xx
Priority to BR9813390-0A priority patent/BR9813390A/pt
Priority to DK98962751T priority patent/DK1036059T3/da
Priority to NZ504447A priority patent/NZ504447A/en
Priority to NO20002786A priority patent/NO20002786L/no
Priority to US09/745,346 priority patent/US6258838B1/en
Priority to US09/745,740 priority patent/US6303659B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9704544A 1997-12-05 1997-12-05 Novel compounds SE9704544D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE9704544A SE9704544D0 (sv) 1997-12-05 1997-12-05 Novel compounds
NZ504447A NZ504447A (en) 1997-12-05 1998-12-01 Substituted-N-(tricyclo[3.3.1.1]dec-1-methyl)-benzamides and their use in treating inflammatory, immune or cardiovascular diseases
DE69808130T DE69808130T2 (de) 1997-12-05 1998-12-01 Adamantan-derivate
CA002312420A CA2312420A1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
CN98813491A CN1284057A (zh) 1997-12-05 1998-12-01 金刚烷衍生物
SK843-2000A SK8432000A3 (en) 1997-12-05 1998-12-01 Adamantane derivatives
AU17913/99A AU744280B2 (en) 1997-12-05 1998-12-01 Adamantane derivatives
HU0004434A HUP0004434A3 (en) 1997-12-05 1998-12-01 Adamantane derivatives and pharmaceuticals containing them
TR2000/01605T TR200001605T2 (tr) 1997-12-05 1998-12-01 Adamantan türevleri.
SI9830276T SI1036059T1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
PCT/SE1998/002188 WO1999029661A1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
EEP200000378A EE200000378A (et) 1997-12-05 1998-12-01 Adamantaani derivaadid
PT98962751T PT1036059E (pt) 1997-12-05 1998-12-01 Derivados de adamantano
KR1020007006132A KR20010032814A (ko) 1997-12-05 1998-12-01 아다만탄 유도체
ES98962751T ES2184352T3 (es) 1997-12-05 1998-12-01 Derivados de adamantano.
AT98962751T ATE224360T1 (de) 1997-12-05 1998-12-01 Adamantan-derivate
JP2000524258A JP2001525392A (ja) 1997-12-05 1998-12-01 アダマンタン誘導体
IDW20001019A ID28003A (id) 1997-12-05 1998-12-01 Turunan-turunan adamantana
IL13636998A IL136369A0 (en) 1997-12-05 1998-12-01 Adamantane derivatives
US09/230,478 US6201024B1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
EP98962751A EP1036059B1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
RU2000117574/04A RU2214997C2 (ru) 1997-12-05 1998-12-01 Производные адамантана, способ их получения, фармацевтическая композиция и способ получения фармацевтической композиции
PL98340906A PL340906A1 (en) 1997-12-05 1998-12-01 Adamantane derivatives
BR9813390-0A BR9813390A (pt) 1997-12-05 1998-12-01 Composto, processo para a preparação do mesmo, e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, processo para efetuar a imunossupressão
DK98962751T DK1036059T3 (da) 1997-12-05 1998-12-01 Adamantanderivater
NO20002786A NO20002786L (no) 1997-12-05 2000-05-31 Adamantanderivater
US09/745,346 US6258838B1 (en) 1997-12-05 2000-12-26 Compounds
US09/745,740 US6303659B2 (en) 1997-12-05 2000-12-26 Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704544A SE9704544D0 (sv) 1997-12-05 1997-12-05 Novel compounds

Publications (1)

Publication Number Publication Date
SE9704544D0 true SE9704544D0 (sv) 1997-12-05

Family

ID=20409281

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704544A SE9704544D0 (sv) 1997-12-05 1997-12-05 Novel compounds

Country Status (25)

Country Link
US (3) US6201024B1 (xx)
EP (1) EP1036059B1 (xx)
JP (1) JP2001525392A (xx)
KR (1) KR20010032814A (xx)
CN (1) CN1284057A (xx)
AT (1) ATE224360T1 (xx)
AU (1) AU744280B2 (xx)
BR (1) BR9813390A (xx)
CA (1) CA2312420A1 (xx)
DE (1) DE69808130T2 (xx)
DK (1) DK1036059T3 (xx)
EE (1) EE200000378A (xx)
ES (1) ES2184352T3 (xx)
HU (1) HUP0004434A3 (xx)
ID (1) ID28003A (xx)
IL (1) IL136369A0 (xx)
NO (1) NO20002786L (xx)
NZ (1) NZ504447A (xx)
PL (1) PL340906A1 (xx)
PT (1) PT1036059E (xx)
RU (1) RU2214997C2 (xx)
SE (1) SE9704544D0 (xx)
SK (1) SK8432000A3 (xx)
TR (1) TR200001605T2 (xx)
WO (1) WO1999029661A1 (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539185A (ja) * 1999-03-16 2002-11-19 グラクソ グループ リミテッド 核内受容体アリール化化合物
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
SE524952C2 (sv) * 2001-09-02 2004-10-26 Sandvik Ab Duplex rostfri stållegering
SE524951C2 (sv) * 2001-09-02 2004-10-26 Sandvik Ab Användning av en duplex rostfri stållegering
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
US7582309B2 (en) * 2002-11-15 2009-09-01 Etex Corporation Cohesive demineralized bone compositions
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1626962B1 (en) * 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
RU2350354C2 (ru) * 2003-05-29 2009-03-27 Астразенека Аб ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТАГОНИСТ Р2Х7 РЕЦЕПТОРА И ФАКТОР НЕКРОЗА ОПУХОЛИ α
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
PE20051141A1 (es) 2004-02-20 2006-01-30 Boehringer Ingelheim Int Inhibidores de la polimerasa viral
MXPA06014022A (es) * 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
EP1763353A1 (en) * 2004-06-29 2007-03-21 Warner-Lambert Company LLC COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR
WO2006003513A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
PE20061490A1 (es) * 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
CA2645556C (en) 2006-03-16 2016-05-24 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ES2596532T3 (es) 2006-03-16 2017-01-10 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
PL2049478T3 (pl) 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
PE20091225A1 (es) 2007-03-22 2009-09-16 Astrazeneca Ab Derivados de quinolina como antagonistas del receptor p2x7
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
MX2009010523A (es) 2007-04-10 2009-12-15 Lundbeck & Co As H Análogos de amidas heteroarílicas como antagonistas de p2x7.
RS54303B1 (en) 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-MEMBER HETEROCYCLIC AMIDES AND RELATED UNITS
WO2009073300A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
ATE494926T1 (de) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
RU2386616C2 (ru) 2008-04-23 2010-04-20 Общество С Ограниченной Ответственностью "Бинатех" Производные 5-гидрокси-4-аминометил-1-циклогексил (или циклогептил)-3-алкоксикарбонилиндолов, их фармацевтически приемлемые соли, обладающие противовирусной активностью, и способ их получения
EP2385939A1 (en) * 2008-12-23 2011-11-16 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
WO2010072605A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
JP2012513435A (ja) 2008-12-23 2012-06-14 エフ.ホフマン−ラ ロシュ アーゲー P2x7調節薬としてのジヒドロピリドンアミド
PT2243772E (pt) 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e sua utilização
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
WO2011143430A1 (en) 2010-05-12 2011-11-17 Abbott Laboratories Indazole inhibitors of kinase
SG185400A1 (en) 2010-05-14 2012-12-28 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101957843B1 (ko) * 2011-10-06 2019-03-14 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN104994857A (zh) * 2012-10-11 2015-10-21 格吕伦塔尔有限公司 Tspo介导的疾病和/或障碍的治疗和/或预防
EA029644B1 (ru) * 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EP2935211B1 (en) * 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2016032182A1 (ko) * 2014-08-29 2016-03-03 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
KR102529578B1 (ko) 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
WO2020037350A1 (en) * 2018-08-24 2020-02-27 The University Of Sydney Adamantanyl-substituted benzamide compounds and their use as p2x7 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) * 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
CA2015473C (en) * 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
EP0720601B1 (en) * 1993-08-10 2000-10-25 James Black Foundation Limited Gastrin and cck receptor ligands
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands

Also Published As

Publication number Publication date
JP2001525392A (ja) 2001-12-11
BR9813390A (pt) 2000-10-03
US6201024B1 (en) 2001-03-13
DE69808130D1 (de) 2002-10-24
EE200000378A (et) 2001-12-17
US6258838B1 (en) 2001-07-10
HUP0004434A2 (hu) 2001-05-28
DE69808130T2 (de) 2003-05-28
NO20002786D0 (no) 2000-05-31
SK8432000A3 (en) 2000-12-11
AU1791399A (en) 1999-06-28
NO20002786L (no) 2000-07-31
KR20010032814A (ko) 2001-04-25
US6303659B2 (en) 2001-10-16
EP1036059B1 (en) 2002-09-18
PT1036059E (pt) 2003-02-28
EP1036059A1 (en) 2000-09-20
HUP0004434A3 (en) 2002-12-28
ID28003A (id) 2001-05-03
RU2214997C2 (ru) 2003-10-27
US20010003121A1 (en) 2001-06-07
TR200001605T2 (tr) 2000-10-23
CN1284057A (zh) 2001-02-14
IL136369A0 (en) 2001-06-14
WO1999029661A1 (en) 1999-06-17
DK1036059T3 (da) 2002-12-02
ES2184352T3 (es) 2003-04-01
AU744280B2 (en) 2002-02-21
CA2312420A1 (en) 1999-06-17
NZ504447A (en) 2002-04-26
PL340906A1 (en) 2001-03-12
ATE224360T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
SE9704546D0 (sv) Novel compounds
MY125978A (en) Admantane derivatives
SE9904505D0 (sv) Novel compounds
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
AP9801392A0 (en) Concentrated antibody preparation.
EE200000318A (et) Uudsed ühendid
SE9901875D0 (sv) Novel compounds
ATE231872T1 (de) Thiazolopyrimidinderivate
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
GR990100140A (el) Νεες ενωσεις
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
SE9802937D0 (sv) Novel compounds
ZA9610460B (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IL134039A0 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them
PT83253A (en) Process for preparing p-acylaminobenzamides
SE9803277D0 (sv) Novel compounds
ZA9811804B (en) 11ß-halogen-7Ó-substituted estratrienes, process for the production of pharmaceutical preparations that contain these 11ß-halogen-7Ó-substituted estratrienes as well as their use for the production of pharmaceutical agents.